Incyte logo

INCY - Incyte News Story

$83.1 0.5  0.6%

Last Trade - 6:05pm

Sector
Healthcare
Size
Large Cap
Market Cap £12.89bn
Enterprise Value £11.52bn
Revenue £1.92bn
Position in Universe 628th / 6846

BRIEF-Lilly And Incyte Announce Results From Phase 3 Cov-Barrier Study Of Baricitinib In Hospitalized Covid-19 Patients

Thu 8th April, 2021 11:48am
April 8 (Reuters) - Incyte Corp  INCY.O :
    * LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3
COV-BARRIER
STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
    * INCYTE CORP - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED
STUDY
OF 1,525 PATIENTS DID NOT MEET STATISTICAL SIGNIFICANCE ON
PRIMARY ENDPOINT
    * INCYTE - DATA SHOWED 38% REDUCTION IN MORTALITY BY DAY 28
IN
PATIENTS TREATED WITH BARICITINIB IN ADDITION TO STANDARD OF
CARE
    * INCYTE CORP - FREQUENCY OF ADVERSE EVENTS AND SERIOUS
ADVERSE
EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
    * INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO
USE
OF BARICITINIB WERE IDENTIFIED
    * INCYTE CORP - TRIAL SHOWED LARGEST EFFECT REPORTED TO DATE
FOR
REDUCTION IN MORTALITY OBSERVED FOR THIS CERTAIN PATIENT
POPULATION WITH COVID-19

Source text for Eikon:  ID:nPn5fSRNBa 
Further company coverage:  INCY.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.